Why Telehealth Platforms Need Built-In Vitals Capture

The telehealth market has moved past the question of whether virtual care works. Adoption is permanent. Health systems, payers, and patients have accepted video visits as a standard care modality. The question now is which telehealth platforms will capture the next wave of enterprise value, and which will become commoditized video call utilities.

The dividing line is clinical capability. Specifically, whether your platform can deliver clinical data during virtual visits or whether it remains a two-way camera with scheduling features. Vital signs capture is the most immediate and impactful clinical capability a telehealth platform can add, and remote photoplethysmography (rPPG) has made it possible without requiring patients to own any hardware.

This is the business case for building vitals into your platform now.

The Gap in Current Telehealth

Every telehealth platform on the market today has converged on essentially the same feature set: video calling, scheduling, messaging, prescription management, and some form of EHR integration. The differences between platforms are marginal. User interface variations, notification workflows, and administrative dashboards are all optimizable but none are defensible differentiators.

The conspicuous absence across all of these platforms is clinical measurement. When a patient connects for a virtual visit, the provider sees a face on a screen. They can observe general appearance, listen to the patient describe symptoms, and review historical records. But they cannot measure anything in real time.

This is not how medicine works. In every other care delivery setting, physiological measurement is the foundation of the clinical encounter. Blood pressure, heart rate, respiratory rate, oxygen saturation, and temperature are captured at every visit because they change clinical decisions. A heart rate of 110 BPM in a patient reporting fatigue points toward a different workup than a heart rate of 68 BPM with the same complaint. An SpO2 of 91 percent in a patient with a cough changes the urgency calculus entirely.

Telehealth platforms that cannot capture this data force providers to either make decisions with less information, defer to in-person visits for data collection, or instruct patients to purchase consumer health devices and self-report readings. None of these outcomes are satisfactory for the provider, the patient, or the platform.

Market Demand from Health Systems

Health system buyers are explicitly asking for vitals capability. As telehealth program maturity increases, clinical leadership is pushing back on the limitations of video-only encounters. The requests follow a pattern:

Chief Medical Officers want clinical data to support care quality metrics and reduce the perception that telehealth delivers inferior care compared to in-person visits. They need measurable evidence that virtual encounters are clinically substantive.

Chief Nursing Officers want tools that support nursing assessments during virtual triage and follow-up visits. Vital signs are the most fundamental element of nursing assessment, and their absence in telehealth creates workflow gaps.

VP of Digital Health teams want differentiated capabilities that justify continued investment in virtual care infrastructure. They are being asked to demonstrate ROI, and clinical data capture is a tangible capability improvement they can point to.

CIOs want platforms that integrate with their clinical systems and contribute structured data to the patient record. Vitals data that flows into the EHR has concrete value for population health analytics, quality reporting, and care coordination.

These are not theoretical conversations. They are showing up in RFPs, in vendor scorecards, and in contract renewal negotiations. Platforms that can demonstrate vitals capture have a material advantage in competitive evaluations.

Competitive Landscape

The telehealth platform market segments into three tiers based on clinical capability:

Tier 1: Video-only platforms. These offer a reliable video connection, scheduling, and basic administrative features. They compete primarily on price and ease of deployment. Margins are thin and switching costs are low because the platform is essentially interchangeable.

Tier 2: Connected device platforms. These integrate with wearables and Bluetooth-connected devices (pulse oximeters, blood pressure cuffs, thermometers) to capture vitals data from patients who own the hardware. The limitation is obvious: most patients do not own clinical-grade devices, and the platforms that depend on them see low utilization rates for vitals features outside of dedicated RPM programs.

Tier 3: Integrated measurement platforms. These use the patient's existing device camera to capture vitals contactlessly during the visit, requiring no additional hardware. This category is emerging, and the platforms that move into it first will define the standard.

The strategic opportunity is in tier 3. Contactless vitals capture removes the hardware barrier that has limited tier 2 platforms and creates a clinical capability that tier 1 platforms cannot replicate through incremental feature development. It is a step function improvement, not an incremental one.

Revenue Impact

Adding vitals capture affects revenue through multiple channels.

Premium Pricing

Vitals-enabled visits are more clinically valuable than video-only visits. Health systems recognize this and are willing to pay more for platforms that deliver clinical data. The pricing uplift is typically structured as a per-visit premium (an additional fee for visits where vitals are captured) or as a platform tier upgrade (vitals capability unlocks the enterprise tier with a higher per-provider license fee).

Platforms that have introduced vitals capability report per-provider pricing increases of 15 to 30 percent when vitals are bundled into the platform tier, with health system buyers accepting the premium because it addresses a documented clinical need.

Enterprise Contract Expansion

Vitals capability opens conversations with enterprise buyers who previously dismissed telehealth as insufficient for their clinical workflows. Specialty departments like cardiology, pulmonology, and endocrinology have resisted telehealth adoption in part because of the inability to capture relevant physiological data. A platform that can deliver heart rate, HRV, SpO2, and respiratory rate addresses these objections and expands the addressable department count within each health system.

More departments using the platform means larger contracts, higher utilization, and stronger net revenue retention.

Reduced Churn

Platform churn in telehealth correlates strongly with perceived clinical value. When providers view the platform as "just a video call," they are ambivalent about which platform they use, and switching decisions get made on price alone. When the platform delivers clinical data that providers rely on for decision-making, it becomes embedded in the clinical workflow. Switching costs increase because providers have built habits around the vitals data, and historical trend data has longitudinal value.

Platforms with clinical data capture report significantly lower annual provider churn rates compared to video-only platforms, because the platform has crossed the threshold from utility to clinical tool.

Remote Patient Monitoring Revenue

CMS has expanded reimbursement for remote patient monitoring (RPM) services, and rPPG vitals capture creates a natural bridge between synchronous telehealth visits and asynchronous monitoring. Patients who measure vitals during a video visit can also perform self-service measurements between visits using the same technology, generating the data streams that support RPM billing codes.

For platforms serving health systems that bill RPM services, this is a direct revenue enablement feature. The platform facilitates data capture that supports CPT codes 99453, 99454, 99457, and 99458, which represent a meaningful per-patient-per-month revenue opportunity for the health system and a strong retention incentive for the platform.

Regulatory Tailwinds

The regulatory environment is moving in favor of telehealth platforms with clinical measurement capabilities.

CMS has permanently expanded coverage for many telehealth services that were temporarily authorized during the pandemic. More importantly, CMS is increasingly tying reimbursement to clinical data documentation. Virtual visits that include documented vital signs meet a higher standard of care documentation, which supports both reimbursement and quality measure reporting.

State parity laws continue to expand, requiring payers to reimburse telehealth at the same rate as in-person visits. As this parity becomes standard, the expectation is that telehealth visits should deliver comparable clinical value, including vital signs capture when clinically relevant.

The Joint Commission and NCQA are developing quality standards for telehealth that will likely include expectations around clinical data capture during virtual encounters. Platforms that already support vitals measurement will be positioned for compliance as these standards formalize.

Buy vs. Build: Why rPPG SDK Integration Wins

For telehealth platform engineering teams, the question is whether to build rPPG capability in-house or integrate an existing SDK. The answer is unambiguous for any team that has seriously evaluated both options.

The Build Path

Building rPPG in-house requires expertise in computer vision, signal processing, and photoplethysmography. The research literature on rPPG is substantial, but translating published algorithms into a production system that works reliably across diverse skin tones, lighting conditions, cameras, and device capabilities is a multi-year engineering effort.

The clinical validation alone, establishing that your implementation produces accurate results across populations, requires formal studies, regulatory expertise, and a sustained investment in accuracy monitoring. A minimum viable rPPG implementation that works in controlled conditions is achievable in six to twelve months. A production-grade system validated for clinical use across the real-world conditions your users will encounter takes two to three years and a dedicated team.

During that development period, your competitors who integrate an existing SDK will be shipping vitals capability, winning enterprise deals, and establishing market position.

The Integrate Path

Integrating a proven rPPG SDK like Circadify's compresses the timeline from years to weeks. The signal processing, clinical validation, cross-device optimization, and accuracy monitoring are already done. Your engineering team focuses on the integration work they are uniquely positioned to do well: connecting the SDK to your video pipeline, building the provider UX, wiring vitals data into your backend and EHR integrations, and designing the clinical workflow.

The economics favor integration as well. The SDK cost is a fraction of the fully loaded cost of a specialized engineering team, and you begin generating revenue from the capability immediately rather than investing for years before seeing returns.

Ongoing Maintenance

rPPG accuracy is not a solve-once problem. Browser updates, new camera hardware, and evolving clinical standards require continuous algorithm updates and validation. An SDK provider absorbs this maintenance burden and delivers improvements through SDK updates. An in-house implementation requires ongoing investment just to maintain current accuracy, before any improvement work begins.

Why Now

The telehealth market is at an inflection point. The pandemic-driven adoption surge has settled into stable, structural demand. Health systems are rationalizing their telehealth vendor portfolios, consolidating from multiple point solutions to fewer, more capable platforms. The vendors that survive this consolidation will be those that offer clinical value beyond video connectivity.

Simultaneously, rPPG technology has matured to the point where it is accurate, fast, and deployable in a browser without specialized hardware. Five years ago, camera-based vitals were a research topic. Today, they are a production-ready capability waiting to be integrated.

The window for first-mover advantage is open but narrowing. As more platforms add vitals capability, it will shift from a differentiator to a table stakes feature. The platforms that move now capture the premium pricing, win the competitive evaluations, and build the longitudinal data assets that create lasting advantage. The platforms that wait will be forced to add vitals capability defensively, at commodity pricing, after the market has already assigned the premium to the early movers.

The strategic question is not whether to add vitals to your telehealth platform. It is whether to do it now, while it is a competitive advantage, or later, when it is merely a requirement.